Accelerating the discovery, development and delivery of precision medicine.
M2Gen provides health informatics solutions to identify and meet patients' needs.

M2Gen® is a health informatics solutions company focused on accelerating the discovery, development and delivery of precision medicine. Our Company was founded in 2006 at the Moffitt Cancer Center to operationalize the Total Cancer Care® Protocol, a unique approach to studying patients throughout their lifetime. In this effort, we partner with the nation’s leading cancer centers via the Oncology Research Information Exchange Network (ORIEN).

Total Cancer Care®is one the world’s largest observational research studies in cancer. TCC represents a true partnership with patients who donate their clinical data and tissue so that we may learn from their experiences and develop evidence-based approaches to meet their needs. Consented patients agree to be contacted for future studies, playing an active role in the study of their cancer and improving care for future generations.

The Oncology Research Information Exchange Network ( ORIEN ) is a unique research partnership among the nation’s leading cancer centers that recognize collaboration and access to data are the keys to advancing cancer discovery, and delivering improved cancer care. Members agree to use the Total Cancer Care protocol and share data to advance the discovery and development of new therapies.

M2Gen provides informatics-based solutions to accelerate the discovery, development and delivery of precision medicine. We work with research groups to provide targeted datasets. If you would like to find out if M2Gen has your dataset of interest, please complete our query form.

Using the information learned from patients through the Total Cancer Care® Protocol, and in partnership with our ORIEN Members, we work with biopharmaceutical companies to address the most challenging questions in drug development. Total Cancer Care provides a harmonized approach to link longitudinal clinical data with molecular information, enabling a much deeper understanding of a patient’s disease. This “opt-in” approach allows for patients to be re-contacted for further studies, creating an information-driven ecosystem to accelerate cancer research.

Our core solution, ORIEN Avatar TM is a pre-competitive informatics environment featuring a robust integrated clinical and molecular dataset combined with proprietary software tools to power discovery and development. We also work with leading biopharmaceutical companies on projects featuring informatics-based approaches to target and biomarker discovery, trial design and enrollment and post-market analysis.

William (Bill) S. Dalton, Ph.D., M.D.

Founder and Executive Chair of M2Gen

Dr. William (Bill) S. Dalton is Founder and Executive Chair. He is the former CEO of M2Gen (2012-2017) and past President, CEO & Center Director of Moffitt Cancer Center, an NCI-Designated Comprehensive Cancer Center (2002-2012). During his tenure as CEO of Moffitt, he led the development of the Total Cancer Care program and creation of the Health Research Informatics platform designed to follow patients throughout their lifetime. He holds several patents in the area of personalized medicine and computer networking. In 2014, Moffitt Cancer Center, in partnership with the James Cancer Center at the Ohio State University, founded the cancer center alliance called ORIEN, Oncology Research Information and Exchange Network, with the goal of accelerating cancer research discovery by sharing information and delivering hope through collaborative learning and partnerships.

Joseph R. Smith, CPA, CGMA

Senior Vice President, Chief Financial Officer of M2Gen

Joseph R. Smith, CPA, CGMA, currently serves as the Senior Vice President and Chief Financial Officer for M2Gen, a wholly owned for profit subsidiary of Moffitt Cancer Center. In this role, Joe is responsible for the financial, marketing and sales aspects of M2Gen and provides leadership for the day to day financial and operational aspects of the business. Prior to joining M2Gen Joe served as Chief Operating Officer and Chief Financial Officer for Bisk Education and also was the CFO, Secretary and Treasurer for a private then public dental practice management company. Joe started his career in public accounting at Deloitte, rose to the level of Partner and was in charge of the middle market practice in the Tampa, Florida office. He holds a BSBA in Accounting with Honors from University of Florida.

Odalys Capote

VP Chief Administrative Officer, M2Gen

Odalys Capote serves as the Vice President/Chief Administrative Officer for M2Gen overseeing human resources, compliance, Board relations and growth of the Oncology Research Information Exchange (ORIEN). Over her career in healthcare, Odalys has held positions as Chief of Staff and Compliance & Privacy Officer, and has prior experience in cost accounting/decision support system implementation, project management and consulting. While at M2Gen, she also held a leadership role in the creation and operationalization of the Oncology Research Information Exchange Network (ORIEN) and the novel ORIEN Clinical Trials Network. She holds a Bachelor’s degree in Marketing from the University of South Florida School of Business.

Judy Barkal

Vice President and Chief Technology / Medical Informatics Officer, M2Gen

Judy Barkal currently serves as the Vice President and Chief Technology / Medical Informatics Officer at M2Gen. She brings deep experience in strategy, innovation and complex business and technology transformation. Judy’s most recent role was Head of Information Strategy and Innovation at Knight Cancer Institute, Oregon Health and Science University. At OHSU, Judy established a cancer informatics strategic roadmap and, as PI, led the creation of a clinical data repository integrated with genomics data to serve multiple cancer researchers and programs. Judy was previously a Partner at IBM, Global Business Services where she led complex business and technology transformations globally in financial services, healthcare, energy, and retail. Prior to IBM, Judy specialized in clusters and high performance computing at Sequent Computer Systems. In her early career, she developed safety-critical, real-time flight control systems at Rockwell Collins.

Stan Micek

Vice President and Chief Commercial Officer, M2Gen

Stan brings to M2Gen significant life sciences experience, including leadership roles within multiple aspects of the branded and generic pharmaceutical product value chain, new business ventures and negotiation of several, large corporate transactions.

Prior to joining M2Gen, Stan served as the Director, Oncology Commercialization at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James). From 2014 to 2016, Stan was the Director of Licensing for The Ohio State University’s (OSU) Technology Commercialization Office. Prior to joining OSU, Stan held executive roles within two mid-sized pharmaceutical companies (Xanodyne Pharmaceuticals and AAIPharma) leading their corporate/ business development functions, specifically in- and out- licensing, acquisitions and divestitures.

For over 19 years at Abbott Laboratories he held positions of increasing responsibility in several functional areas, including national account sales, marketing, business development and licensing, engineering and international manufacturing/ operations.

Stan earned his B.Sc. in Chemical Engineering from the Illinois Institute of Technology in Chicago and his MBA in Marketing and International Management from Northwestern University’s Kellogg Graduate School of Management in Evanston, IL.

Oliver Hampton, Ph.D.

Vice President, Bioinformatics and Biostatistics

Oliver Hampton, PhD, currently serves as the VP of Bioinformatics and Biostatistics for M2Gen. Oliver leads the bioinformatics team and is building the biostatistics team to support the Avatar project, as well as collaborative projects between M2Gen, Pharma and ORIEN partners. Oliver comes to M2Gen with great expertise in Next-Generation-Sequencing, having led the Platform Informatics team, Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center. Prior to that, Oliver was an Assistant Professor at Baylor College of Medicine.

Board Members

William (Bill) S. Dalton, Ph.D., M.D. (Chair)

Executive Chair of the Board - M2Gen

Timothy J. Adams

President (Retired) - Time Customer Service, Inc.

James M. Asher

Senior Vice President, Chief Legal & Development Officer - Hearst

Gregory Dorn, MD, MPH

President - Hearst Health

Alan List, MD

President and CEO - Moffitt Cancer Center

Richard P. Malloch

President - Hearst Business Media

Allan Martin

Co-Founder and Chief Executive Officer - Lumina Analytics

Thomas Sellers, PhD, MPH

Center Director & Executive Vice President - Moffitt Cancer Center & Research Institute

Frederick J. Lynch

Chief Executive Officer and President (Retired) - Masonite International Corporation

Board Observers

Raphael Pollock, MD, PhD, FACS

Director, The Ohio State University Comprehensive Cancer Center Kathleen Wellenreiter Klotz Chair in Cancer Research

Steve Swartz

President and Chief Executive Officer - Hearst

We are hiring! Please see our open positions at our parent company Careers Site.

Oct. 26, 2017
M2Gen® Announces Bristol-Myers Squibb's Participation in ORIEN Avatar™ Research Program
Read more
Sept. 20, 2017
Hearst investment to aid cancer research
Read more
Aug. 23, 2017
M2Gen Names New Executive Chair and New President and Chief Executive Officer
Read more
Mar. 28, 2017
AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program
Read more
Jan. 5, 2017
M2Gen Announces that Merck Joins the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program
Read more
Sep 22, 2016
M2Gen Selects DNAnexus to Manage Molecular Data for ORIEN Avatar Research Program
Read more
Sep 12, 2016
ORIEN Cancer Initiative and HudsonAlpha Announce Collaboration to Accelerate the Development of Personalized Cancer Therapies
Read more
Apr 07, 2016
Leading Cancer Centers and Biopharmaceutical Companies Launch Unprecedented Alliance to Advance Development of Precision Medicines for Cancer Patients
Read more
Mar 08, 2016
PatientsLikeMe and M2Gen Announce Partnership and Plans for Landmark Cancer Experience Study.
Read more